

1 **Article Summary Line:** In South Africa, after a third wave of SARS-CoV-2 infections,
2 seroprevalence was 60% in a rural and 70% in an urban community, with case-to-infection, -
3 hospitalization and -fatality ratios similar to the second wave.

4 **Running title:** SARS-CoV-2 seroprevalence, South Africa, 2021

5 **Keywords:** SARS-CoV-2, seroprevalence, case-to-infection ratio, case-to-hospitalization
6 ratio, case-to-fatality ratio

7

8 **SARS-CoV-2 seroprevalence in a rural and urban community household cohort in**
9 **South Africa, after the third wave, April-November 2021**

10 Jackie Kleynhans (MPH), Stefano Tempia (PhD), Nicole Wolter (PhD), Anne von Gottberg
11 (PhD), Jinal N. Bhiman (PhD), Amelia Buys (MTech), Jocelyn Moyes (MD), Meredith L.
12 McMorrow (MD), Kathleen Kahn (PhD), F. Xavier Gómez-Olivé (PhD), Stephen Tollman
13 (PhD), Neil A. Martinson (MD), Floidy Wafawanaka (MSc), Limakatso Lebina (MD),
14 Jacques du Toit (MD), Waasila Jassat (MD), Mzimasi Neti (MPH), Marieke Brauer (MMed
15 Path), Cheryl Cohen (PhD), for the PHIRST-C Group¹

16 **Author affiliations**

17 National Institute for Communicable Diseases of the National Health Laboratory Service,
18 Johannesburg, South Africa (J. Kleynhans, S. Tempia, N. Wolter, A. von Gottberg, J.N.

19 Bhiman, A. Buys, J. Moyes, W. Jassat, M. Neti, C. Cohen)

20 University of the Witwatersrand, Johannesburg, South Africa (J. Kleynhans, S. Tempia, N.

21 Wolter, A. von Gottberg, J.N. Bhiman, J. Moyes, C. Cohen)

22 Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America (S.
23 Tempia, M.L. McMorrow)

24 Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa (M.L.
25 McMorrow)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), University
27 of the Witwatersrand, Johannesburg, South Africa (K. Kahn, F.X. Gómez-Olivé, S. Tollman,
28 F. Wafawanaka, J. du Toit)

29 Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South
30 Africa (N.A. Martinson, L. Lebina)

31 Johns Hopkins University Center for TB Research, Baltimore, Maryland, United States of
32 America (N.A. Martinson)

33 Africa Health Research Institute, Durban, South Africa (L. Lebina)

34 Ampath Pathology, Pretoria, South Africa (M. Brauer)

35 ¹Additional members of the PHIRST-C group who contributed to this manuscript are listed at
36 the end of this article

37 **Abstract (words 50/50)**

38 By November 2021, after the third SARS-CoV-2 wave in South Africa, seroprevalence was
39 60% (95%CrI 56%-64%) in a rural and 70% (95%CrI 56%-64%) in an urban community;
40 highest in individuals aged 13-18 years. High seroprevalence prior to Omicron emergence
41 may have contributed to reduced severity observed in the 4th wave.

42

43 Word count (756/800)

44 South Africa so far experienced four waves of SARS-CoV-2 infection, the fourth dominated
45 by the Omicron variant of concern (1). Data on the proportion of the population with
46 serologic evidence of previous infection at the time of Omicron emergence are important to
47 contextualise the observed rapid increases and subsequent quick decline in case numbers, (1)
48 as well as the lower severity compared to previous variants (2).

49 We previously described the seroprevalence of SARS-CoV-2 in the PHIRST-C cohort in a
50 rural and an urban community at five time points, from July 2020 to March 2021 (3). Using
51 the same methods (Appendix), we report seroprevalence at four additional time points
52 through November 27, 2021, spanning the third Delta-dominated wave (Appendix Figure 1),
53 ending the week Omicron was identified (4). We tested sera using the Roche Elecsys® Anti-
54 SARS-CoV-2 assay (Roche Diagnostics, Rotkreuz, Switzerland); cut-off index (COI) \geq 1.0
55 considered indication of prior infection. The immunoassay detects nucleocapsid (N)
56 antibodies, thus not detecting post-vaccination antibody responses. We obtained
57 seroprevalence 95% credible intervals (CrIs) by using Bayesian inference with 10,000
58 posterior draws (5). We estimated the age- and sex-adjusted number of infections, and age-
59 adjusted diagnosed cases, hospitalizations, deaths, case-to-infection ratio (CIR), case-to-
60 hospitalization ratio (HIR) and in-hospital and excess death case-to-fatality ratio (FIR) as
61 described previously (3) and in Appendix. Third wave infections were defined as participants
62 with a paired blood draw (BD) 5 (collected March 22 – April 11, 2021) and BD9 (collected
63 November 15 – 27, 2021) sample, seronegative at BD5 and seropositive at BD9, or
64 seropositive at BD5 but had a \geq 2-fold higher COI in BD9 (as possible re-infections after BD5
65 occurred, n=38, detailed in Appendix). Vaccination status was obtained through reviewing
66 vaccine cards kept at home. The study was approved by the University of the Witwatersrand
67 Human Research Ethics Committee (Reference 150808) and the US Centers for Disease
68 Control and Prevention relied on local clearance (IRB #6840).

69 Overall, pre-third wave (BD5) SARS-CoV-2 seroprevalence adjusted for assay sensitivity
70 and specificity was 26% (95% CrI 22%-29%) in the rural and 41% (95% CrI 37%-45%) in
71 the urban community. After the third wave (BD9), overall seroprevalence increased to 60%
72 (95% CrI 56%-64%) in the rural community and 70% (95% CrI 66%-74%) in the urban
73 community (Figure, Appendix Table 1). In both communities the largest increase in
74 seroprevalence was seen in children aged 13-18 years, who also had the highest
75 seroprevalence of all ages after the third wave: 80% (95% CrI 70%-88%) in the rural
76 community and 83% (95% CrI 73%-90%) in the urban community, a 49% and 19% increase,
77 respectively.

78 During the third wave of infections, the incidence at the rural site was 39% (95%CrI 24%-
79 55%), resulting in a CIR of 3% (95%CI 2%-5%). There was a 0.5% (95%CI 0.3%-0.7%) HIR
80 and an in-hospital FIR of 0.1% (95%CI 0.1%-0.2%) and an excess deaths FIR of 0.5%
81 (95%CI 0.4%-0.8%, Figure and Appendix Figure 2).

82 In the urban community the incidence during the third wave was 40% (95%CrI 26%-54%).
83 There was a 5% (95%CI 4%-8%) CIR and 2% (95%CI 2%-4%) HIR. The in-hospital FIR
84 was 0.4% (95%CI 0.3%-0.6%) and excess deaths FIR 0.6% (95%CI 0.4-0.9%, Figure and
85 Appendix Figure 2).

86 At the time of BD9, for those individuals in the rural community with a known vaccination
87 status, 29% (25/85) of individuals aged 35-59 years, and 38% (16/42) aged ≥ 60 years were
88 fully vaccinated against SARS-CoV-2 (one dose of Johnson & Johnson or two doses of
89 Pfizer-BioNTech). In the urban community, 42% (47/111) aged 35-59 years and 58% (31/53)
90 aged ≥ 60 years were fully vaccinated (Appendix Table 2).

91 Taken together, by the end of November 2021, just prior to the emergence of Omicron, the
92 combined proportion of individuals with either serologic evidence of previous infection (at

93 any draw) and/or fully vaccinated was 62% (389/631) at the rural and 72% (411/568) at the
94 urban community (Appendix Table 3).

95 After the third wave of infections in South Africa, we observed a $\geq 60\%$ overall
96 seroprevalence due to SARS-CoV-2 infection, ranging from 43% in rural community
97 children aged <5 years to 83% in urban community children aged 13-18 years (Figure). CIF,
98 HIR and FIRs were similar between the second and third waves. Similar to our data, a study
99 from Gauteng Province found seroprevalence of 56%-80% due to natural infection prior to
100 the emergence of Omicron (6). The high seroprevalence prior to Omicron emergence may
101 have contributed to reduced severity observed in the 4th wave (2). Future studies examining
102 SARS-CoV-2 attack rates using paired serology will be important to help understand how
103 immunity affects disease severity in the population during the fourth Omicron wave.

104 **Additional members of the PHIRST-C group who contributed to this manuscript**

105 Kgaugelo Patricia Kgasago, Linda de Gouveia, Maimuna Carrim, Mignon du Plessis,
106 Retshidisitswe Kotane, Tumelo Moloantoa

107 **Acknowledgements**

108 All individuals participating in the study, field teams for their hard work and dedication to the
109 study, the laboratory teams, the PHIRST-C scientific and safety committee, the national
110 SARS-CoV-2 NICD surveillance team, NICD IT.

111 **Disclaimer**

112 The findings and conclusions in this report are those of the authors and do not necessarily
113 represent the official position of the CDC.

114 **Funding**

115 This work was supported by the National Institute for Communicable Diseases of the
116 National Health Laboratory Service and the US Centers for Disease Control and Prevention
117 (cooperative agreement number 6U01IP001048-04-02 awarded to C Cohen). The funders had
118 no role in study design, data collection and analysis, decision to publish, or preparation of the
119 manuscript.

120 **Potential conflicts of interest**

121 Cheryl Cohen reports receiving grant funds from US-Centers for Disease Control and
122 Prevention, Wellcome Trust and South African Medical Research Council. Nicole Wolter
123 and Anne von Gottberg report receiving grant funds from Sanofi and Gates Foundation. All
124 other authors have no competing/conflict of interest.

125 **Data availability**

126 The investigators welcome enquiries about possible collaborations and requests for access to
127 the dataset. Data will be shared after approval of a proposal and with a signed data access
128 agreement. Investigators interested in more details about this study, or in accessing these
129 resources, should contact the corresponding author.

130 **References**

- 131 1. National Institute for Communicable Diseases. COVID-19 Weekly Epidemiology Brief Week 3.
132 2022 26 January 2022 [cited 31 January 2022; Available from: [https://www.nicd.ac.za/wp-](https://www.nicd.ac.za/wp-content/uploads/2022/01/COVID-19-Weekly-Epidemiology-Brief-week-3-2022.pdf)
133 [content/uploads/2022/01/COVID-19-Weekly-Epidemiology-Brief-week-3-2022.pdf](https://www.nicd.ac.za/wp-content/uploads/2022/01/COVID-19-Weekly-Epidemiology-Brief-week-3-2022.pdf)
- 134 2. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the
135 clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. The Lancet.
136 2022;339(10323):437-46.

- 137 3. Kleynhans J, Tempia S, Wolter N, von Gottberg A, Bhiman J, Buys A, et al. SARS-CoV-2
138 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections,
139 South Africa, July 2020–March 2021. *Emerging Infectious Disease journal*. 2021;27(12):3020.
- 140 4. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of
141 Concern. 2021 26 November 2021 [cited 5 January 2021 5 January 2021]; Available from:
142 [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern)
143 [variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern)
- 144 5. Larremore DB, Fosdick BK, Bubar KM, Zhang S, Kissler SM, Metcalf CJE, et al. Estimating
145 SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological
146 surveys. *Elife*. 2021;10:e64206.
- 147 6. Madhi SA, Kwatra G, Myers JE, Jassat W, Dhar N, Mukendi CK, et al. South African Population
148 Immunity and Severe Covid-19 with Omicron Variant. *medRxiv*. 2021:2021.12.20.21268096.


149 **Biographical Sketch**

150 Jackie Kleynhans is an epidemiologist in Centre for Respiratory Diseases and Meningitis,
151 National Institute for Communicable Diseases. She holds a Master’s degree in Microbiology
152 and Masters of Public Health from the University of Pretoria, and is an alumnus of the South
153 African Field Epidemiology Training Programme. Her interests include the epidemiology of
154 respiratory diseases like influenza and COVID-19, vaccine impact studies and modelling of
155 infectious disease transmission dynamics.

156 **Address for correspondence**

157 Jackie Kleynhans, Centre for Respiratory Diseases and Meningitis, National Institute for
158 Communicable Diseases of the National Health Laboratory Service, 1 Modderfontein Road,
159 Sandringham, 2192, Johannesburg, South Africa; email: jackiel@nicd.ac.za

160



161

162 **Figure.** SARS-CoV-2 seroprevalence at each blood collection by age group in the a) rural
163 and b) urban community March 2020 - November 2021, South Africa.

164 Baseline (BD1) July 20 – September 17, 2020; second draw (BD2) September 21 – October
165 10, 2020; third draw (BD3) November 23 – December 12, 2020; fourth draw (BD4) January,
166 25 – February 20, 2021; fifth draw (BD5) March 22 – April 11, 2021; sixth draw (BD6) May
167 20 – June 9, 2021; seventh draw (BD7) July 19 – August 5, 2021; eighth draw (BD8)
168 September 13 – 25, 2021; ninth draw (BD9) November 15 – 27, 2021. Vertical capped lines
169 represent 95% credible interval. Seroprevalence estimates adjusted for sensitivity and
170 specificity of assay.